Ultraslow oligomerization equilibria of p53 and its implications

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 34, 2009, Pages 14327-14332

  Natan, Eviatar ^a   Hirschberg, Daniel ^b   Morgner, Nina ^b   Robinson, Carol V ^b   Fersht, Alan R ^a,b  

^a MRC CENTRE FOR PROTEIN ENGINEERING   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Mass spectrometry; Protein protein interactions; Slow association; Tetramerization domain

Indexed keywords

DNA; PROTEIN BAX; PROTEIN P21; PROTEIN P53; TETRAMER;

ALLELE; ARTICLE; BINDING AFFINITY; CANCER CELL; DISSOCIATION CONSTANT; DNA BINDING; DNA DENATURATION; ELECTROSPRAY MASS SPECTROMETRY; HALF LIFE TIME; HUMAN; MOLECULAR MECHANICS; NONHUMAN; OLIGOMERIZATION; ONCOGENE; PRIORITY JOURNAL; WILD TYPE;

AMINO ACID SUBSTITUTION; BINDING, COMPETITIVE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA; HUMANS; KINETICS; MUTANT PROTEINS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS C-BCL-2; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; THERMODYNAMICS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70149100002     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0907840106     Document Type: Article

References (36)

1. Joerger AC, Fersht AR (2008) Structural biology of the tumor suppressor p53. Annu Rev Biochem 77:557-582.
2. Petitjean A, et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622-629. (Pubitemid 46744292)
3. Wells M, et al. (2008) Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain. Proc Natl Acad Sci USA 105:5762-5767. (Pubitemid 351758446)
4. Joerger AC, Fersht AR (2007) Structure-function-rescue: The diverse nature of common p53 cancer mutants. Oncogene 26:2226-2242.
5. Junk DJ, et al. (2008) Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. Neoplasia 10:450-461.
6. Nicholls CD, McLure KG, Shields MA, Lee PW (2002) Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect. J Biol Chem 277:12937-12945.
7. Marutani M, et al. (1999) Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme. Cancer Res 59:4765-4769. (Pubitemid 29472872)
8. Dong P, et al. (2007) p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells. Clin Exp Metastasis 24:471-483. (Pubitemid 47367689)
9. Dearth LR, et al. (2007) Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis 28:289-298.
10. van Dieck J, Fernandez-Fernandez MR, Veprintsev DB, Fersht AR (2009) Modulation of the oligomerization state of p53 by differential binding of proteins of the S100 family to p53 monomers and tetramers. J Biol Chem 284:13804-13811.
11. Cai BH, et al. (2009) Functional four-base A/T gap core sequence CATTAG of P53 response elements specifically bound tetrameric P53 differently than two-base A/T gap core sequence CATG bound both dimeric and tetrameric P53. Nucleic Acids Res 37:1984-1990.
12. Fernandez-Fernandez MR, Veprintsev DB, Fersht AR (2005) Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor. Proc Natl Acad Sci USA 102:4735-4740. (Pubitemid 40471523)
13. Maki CG (1999) Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. J Biol Chem 274:16531-16535. (Pubitemid 129526411)
14. Stommel JM, et al. (1999) A leucine-rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by NES masking. EMBO J 18:1660-1672.
15. Itahana Y, Ke H, Zhang Y (2008) p53 oligomerization is essential for its C-terminal lysine acetylation. J Biol Chem 284:5158-5164.
16. Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM (1989) Electrospray ionization for mass spectrometry of large biomolecules. Science 246:64-71. (Pubitemid 19252085)
17. Sharon M, Robinson CV (2007) The role of mass spectrometry in structure elucidation of dynamic protein complexes. Annu Rev Biochem 76:167-193.
18. Wendt S, et al. (2003) Quantitative evaluation of noncovalent chorismate mutaseinhibitor binding by ESI-MS. J Am Soc Mass Spectrom 14:1470-1476. (Pubitemid 37491048)
19. Keetch CA, et al. (2005) L55P transthyretin accelerates subunit exchange and leads to rapid formation of hybrid tetramers. J Biol Chem 280:41667-41674.
20. Chitta RK, Rempel DL, Gross ML (2005) Determination of affinity constants and response factors of the noncovalent dimer of gramicidin by electrospray ionization mass spectrometry and mathematical modeling. J Am Soc Mass Spectrom 16:1031-1038.
21. Sobott F, Benesch JL, Vierling E, Robinson CV (2002) Subunit exchange of multimeric protein complexes. Real-time monitoring of subunit exchange between small heat shock proteins by using electrospray mass spectrometry. J Biol Chem 277:38921-38929. (Pubitemid 35154757)
22. Nikolova PV, Henckel J, Lane DP, Fersht AR (1998) Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. Proc Natl Acad Sci USA 95:14675-14680. (Pubitemid 29003689)
23. Joerger AC, Allen MD, Fersht AR (2004) Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations. J Biol Chem 279:1291-1296.
24. Tidow H, et al. (2007) Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex. Proc Natl Acad Sci USA 104:12324-12329. (Pubitemid 47206136)
25. Joerger AC, Ang HC, Veprintsev DB, Blair CM, Fersht AR (2005) Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J Biol Chem 280:16030-16037.
26. Bullock AN, Henckel J, Fersht AR (2000) Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: Definition of mutant states for rescue in cancer therapy. Oncogene 19:1245-1256. (Pubitemid 30160617)
27. Aquilina JA, Benesch JL, Bateman OA, Slingsby C, Robinson CV (2003) Polydispersity of a mammalian chaperone: Mass spectrometry reveals the population of oligomers in alphaB-crystallin. Proc Natl Acad Sci USA 100:10611-10616. (Pubitemid 37140077)
28. Friedler A, Veprintsev DB, Hansson LO, Fersht AR (2003) Kinetic instability of p53 core domain mutants: Implications for rescue by small molecules. J Biol Chem 278:24108-24112. (Pubitemid 36830245)
29. Veprintsev DB, Fersht AR (2008) Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA. Nucleic Acids Res 36:1589-1598.
30. Veprintsev DB, et al. (2006) Core domain interactions in full-length p53 in solution. Proc Natl Acad Sci USA 103:2115-2119. (Pubitemid 43271632)
31. Joerger AC, Ang HC, Fersht AR (2006) Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci USA 103:15056-15061.
32. Tidow H, Veprintsev DB, Freund SM, Fersht AR (2006) Effects of oncogenic mutations and DNA response elements on the binding of p53 to p53-binding protein 2 (53BP2). J Biol Chem 281:32526-32533. (Pubitemid 46036807)
33. Weinberg RL, Veprintsev DB, Fersht AR (2004) Cooperative binding of tetrameric p53 to DNA. J Mol Biol 341:1145-1159.
34. Rajagopalan S, Jaulent AM, Wells M, Veprintsev DB, Fersht AR (2008) 14-3-3 activation of DNA binding of p53 by enhancing its association into tetramers. Nucleic Acids Res 36:5983-5991.
35. Sobott F, Hernandez H, McCammon MG, Tito MA, Robinson CV (2002) A tandem mass spectrometer for improved transmission and analysis of large macromolecular assemblies. Anal Chem 74:1402-1407. (Pubitemid 34233333)
36. Nettleton EJ, et al. (1998) Protein subunit interactions and structural integrity of amyloidogenic transthyretins: Evidence from electrospray mass spectrometry. J Mol Biol 281:553-564.